We also confirmed that using anti‐FGF2 monoclonal antibody (3F12E7) could inhibit lymphangiogenesis and lymph node metastasis in the orthotopic lymph node metastasis model. Here, FGF2 is linked to metastatic malignant neoplasm in the lymph nodes.